Synpromics Announces Collaboration With Avalanche Biotech
Edinburgh, UK, 17th December 2015 / Sciad Newswire / Synpromics Ltd, a leading synthetic biology company, is pleased to announce a collaboration with Avalanche Biotechnologies Inc. (Nasdaq: AAVL), a gene therapy company committed to improving or preserving the sight of people with serious eye diseases with an unmet medical need.
Synpromics will develop synthetic promoters for use with Avalanche’s Ocular BioFactory™ platform technology. Synpromics' technology creates highly specific promoters that control gene expression. These promoters are designed to be specific to the target cell type and aim to enable a precise level of control of gene expression.
Dr David Venables, CEO of Synpromics, commented, “This is our fourth collaboration in the field of gene therapy and further validation of the wide applicability of our platform. Avalanche Biotechnologies is developing next generation gene therapy technologies to treat eye diseases and we believe that Synpromics’ technology has the potential to support the development of these next generation therapeutics.”
Synpromics will develop synthetic promoters for use with Avalanche’s Ocular BioFactory™ platform technology. Synpromics' technology creates highly specific promoters that control gene expression. These promoters are designed to be specific to the target cell type and aim to enable a precise level of control of gene expression.
Dr David Venables, CEO of Synpromics, commented, “This is our fourth collaboration in the field of gene therapy and further validation of the wide applicability of our platform. Avalanche Biotechnologies is developing next generation gene therapy technologies to treat eye diseases and we believe that Synpromics’ technology has the potential to support the development of these next generation therapeutics.”